1. Home
  2. CHEK vs BCDA Comparison

CHEK vs BCDA Comparison

Compare CHEK & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHEK
  • BCDA
  • Stock Information
  • Founded
  • CHEK 2004
  • BCDA N/A
  • Country
  • CHEK Israel
  • BCDA United States
  • Employees
  • CHEK N/A
  • BCDA N/A
  • Industry
  • CHEK Medical Electronics
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHEK Health Care
  • BCDA Health Care
  • Exchange
  • CHEK Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • CHEK 9.0M
  • BCDA 7.9M
  • IPO Year
  • CHEK 2015
  • BCDA N/A
  • Fundamental
  • Price
  • CHEK $0.86
  • BCDA $2.63
  • Analyst Decision
  • CHEK
  • BCDA Strong Buy
  • Analyst Count
  • CHEK 0
  • BCDA 1
  • Target Price
  • CHEK N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • CHEK 74.4K
  • BCDA 55.0K
  • Earning Date
  • CHEK 02-25-2025
  • BCDA 03-26-2025
  • Dividend Yield
  • CHEK N/A
  • BCDA N/A
  • EPS Growth
  • CHEK N/A
  • BCDA N/A
  • EPS
  • CHEK N/A
  • BCDA N/A
  • Revenue
  • CHEK N/A
  • BCDA $71,000.00
  • Revenue This Year
  • CHEK N/A
  • BCDA N/A
  • Revenue Next Year
  • CHEK N/A
  • BCDA N/A
  • P/E Ratio
  • CHEK N/A
  • BCDA N/A
  • Revenue Growth
  • CHEK N/A
  • BCDA N/A
  • 52 Week Low
  • CHEK $0.56
  • BCDA $1.63
  • 52 Week High
  • CHEK $3.45
  • BCDA $8.85
  • Technical
  • Relative Strength Index (RSI)
  • CHEK 41.46
  • BCDA 61.81
  • Support Level
  • CHEK $0.81
  • BCDA $2.27
  • Resistance Level
  • CHEK $0.97
  • BCDA $2.78
  • Average True Range (ATR)
  • CHEK 0.10
  • BCDA 0.27
  • MACD
  • CHEK -0.03
  • BCDA 0.02
  • Stochastic Oscillator
  • CHEK 10.44
  • BCDA 77.61

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: